Inflammatory and Cardiometabolic Risk on Obesity: Role of Environmental Xenoestrogens by Teixeira, Diana et al.
Inflammatory and Cardiometabolic Risk on Obesity:
Role of Environmental Xenoestrogens
Diana Teixeira, Diogo Pestana, Cristina Santos, Luísa Correia-Sá,
Cláudia Marques, Sónia Norberto, Manuela Meireles, Ana Faria, Ricardo Silva,
Gil Faria, Carla Sá, Paula Freitas, António Taveira-Gomes, Valentina Domingues,
Cristina Delerue-Matos, Conceição Calhau, and Rosário Monteiro
Departments of Biochemistry (D.T., D.P., S.N., M.M., A.F., R.S., C. Sá, C.C., R.M.), Health Information
and Decision Science (C.San.), Endocrinology, Diabetes and Metabolism (P.F.), S. João Hospital General
Surgery, Pedro Hispano Hospital (A.T.G.), Faculty of Medicine, University of Porto, 4200-319 Porto,
Portugal; Center for Research in Health Technologies and Information Systems (D.P., C.San., G.F., C.C.),
4200-450 Porto, Portugal; Rede de Química e Tecnologia - Instituto Superior de Engenharia (L.C., V.D.,
C.D.M), Instituto Politécnico do Porto, 4200-072 Porto, Portugal; Faculty of Nutrition and Food Sciences
(A.F.), University of Porto, 4200-465 Porto, Portugal; Rede de Química e Tecnologia, Laboratório
Associado de Química Verde (A.F.), Faculdade de Ciências, Universidade do Porto, 4169-009 Porto,
Portugal; and Department of General Surgery, Oporto Hospital Center (G.F.), 4050-313 Porto, Portugal
Context: Some chemicals used in consumer products or manufacturing (eg, plastics, pesticides)
have estrogenic activities; these xenoestrogens (XEs) may affect immune responses and have re-
cently emerged as a new risk factors for obesity and cardiovascular disease. However, the extent
and impact on health of chronic exposure of the general population to XEs are still unknown.
Objective: The objective of the study was to investigate the levels of XEs in plasma and adipose
tissue (AT) depots in a sample of pre- and postmenopausal obese women undergoing bariatric
surgery and their cardiometabolic impact in an obese state.
Design and Participants: We evaluated XE levels in plasma and visceral and subcutaneous AT samples
of Portuguese obese (body mass index  35 kg/m2) women undergoing bariatric surgery. Association
with metabolic parameters and 10-year cardiovascular disease risk was assessed, according to meno-
pausal status (73 pre- and 48 postmenopausal). Levels of XEs were determined by gas chromatography
with electron-capture detection. Anthropometric and biochemical data were collected prior to sur-
gery. Adipocyte size was determined on tissue sections obtained during surgery.
Results: Our data show that XEs are pervasive in this obese population. Distribution of individual
and concentration of total XEs differed between plasma, visceral AT, and subcutaneous AT, and the
pattern of accumulation was different between pre- and postmenopausal women. Significant
associations between XE levels and metabolic and inflammatory parameters were found. In pre-
menopausal women, XEs in plasma seem to be a predictor of 10-year cardiovascular disease risk.
Conclusions: Our findings point toward a different distribution of XE between plasma and AT in
pre- and postmenopausal women, and reveal the association between XEs on the development of
metabolic abnormalities in obese premenopausal women. (J Clin Endocrinol Metab 100:
1792–1801, 2015)
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Polychlorinated pesticides, widespread in the environ-ment, such as metabolites of dichlorodiphenyltrichlo-
roethane, -, - and -hexachlorocyclohexane (HCH), as
well as hexachlorobenzene (HCB) and aldrin, have estro-
genic properties, being called environmental estrogens [xe-
noestrogens (XEs)] (1).
Environmental estrogens have several unique features
that distinguish them from other common chemicals. Due
to their long half-life and lipophilicity, they accumulate in
adipose tissue (AT) and move within the body bound to
lipids (2). Furthermore, humans are exposed to XEs as
chemical mixtures due to the coexistence in the environ-
ment, food webs, and long-term retention in AT, resulting
in virtually everyone in modern society having some XE
exposure (3, 4).
Moreover, there is accumulating evidence of potential
impacts of XE exposure on human health that might be
mediated by a variety of mechanisms, including endocrine
disruption locally at the AT and in components of the
human immune system (5). Additionally, XE bioaccumu-
lation in AT, a dynamic organ involved in the integrative
network that maintains global energy homeostasis, may
result in high local concentrations and lead to metabolic
disruption in adipocytes (6). On the other hand, it is
recognized that chronic low-grade inflammation and an
activation of the immune system are involved in the
pathogenesis of obesity-related comorbidities and the
AT is an important site of inflammation in presence of
obesity (7).
Although recent epidemiological evidence has linked
environmental chemicals with obesity, insulin resistance,
and cardiovascular disease (8–10), few studies link XEs
with the complications arising with obesity when it is al-
ready installed. In this regard, we have recently reported
interesting positive associations between AT concentra-
tions of persistent organic pollutants, some of them with
xenoestrogenic activity, and metabolic abnormalities
among a sample of obese patients undergoing bariatric
surgery. The associations were stronger with chemicals
present in visceral AT (vAT). Furthermore, it was high-
lighted that these anthropogenic chemicals favored dys-
metabolism despite the presence of obesity, proposing a
shift on the focus to their dysmetabolic, and not only the
obesogenic, effect (11).
The reduction of circulatory estrogens is a key factor in
the onset of cardiovascular disease (CVD) during the
menopausal period. Disturbances of this endocrine signal
lead to the development of metabolic syndrome and a
higher CVD risk in women, associated with predominant
abdominal fat accumulation, even if in premenopausal
women (12). However, the relationship between XEs in
the presence/absence of these hormones and the cardio-
metabolic profile of obese women during menopause is
not clear.
Moreover, few studies have reported correlations be-
tween plasma and AT concentrations of certain XEs and
metabolic traits according to menopausal status. Thus, the
present study was performed to investigate the levels of
XEs in plasma and AT depots in a sample of pre- and
postmenopausal obese women undergoing bariatric sur-
gery and their cardiometabolic impact in an obese state.
Materials and Methods
Participants
The study involved 121 obese women (73 premenopausal and
48 postmenopausal as classified after evaluation by clinical en-
docrinology) with an age range of 19–61 years undergoing bari-
atric surgery (gastric banding or Roux-en-Y) at the General Sur-
gery Department, S. João Hospital (Porto, Portugal), who were
recruited between January 2010 and June 2011. Patients met the
criteria for obesity surgery according to the latest criteria of the
country’s Department of Health. This investigation was con-
ducted according to the Declaration of Helsinki, approved by the
hospital’s ethics committee. All participants provided written
informed consent. Sociodemographic characteristics, anthropo-
metric characteristics, clinical history, lifestyle factors, parity,
and occupation were collected from the Medical Support System
of S. João Hospital.
Clinical and biological parameters
Anthropometrics, adiposity-related markers, and various
clinical variables were measured at baseline. Body mass index
(BMI; kilograms per square meter) was calculated from the mea-
sured body weight and height. Analysis of blood samples col-
lected after an overnight fast was performed in the Department
of Clinical Pathology of S. João Hospital. Routine serum chem-
istries were measured using conventional methods with an
Olympus AU5400 automated clinical chemistry analyzer (Beck-
man-Coulter, Izasa). Biological parameters evaluated included
fasting blood glucose and insulin, lipid profile [total cholesterol,
high density lipoprotein (HDL) cholesterol, low density lipopro-
tein (LDL) cholesterol, and triglycerides] and high-sensitivity
C-reactive protein (hsCRP). LDL cholesterol was calculated
according to Friedewald’s equation (13). The homeostasis
model assessment value for insulin resistance (HOMA-IR)
and -cell function (HOMA-2B) were calculated as described
previously (14). Lastly, we used the Framingham risk score to
estimate the 10-year CVD risk (a person’s chance of develop-
ing CVD in the next 10 years) of these individuals (15).
Assessment of XE concentrations in plasma and
adipose tissue
XEs were quantified in plasma samples stored at 80°C col-
lected prior to surgery. The samples were analyzed by a previ-
ously published methodology (16), with some modifications, in-
volving solid-phase extraction and a final determination using a
gas chromatograph coupled to an electron capture detector. A
total of five XEs were measured: aldrin (purchased from Pes-
tanal; Fluka), p,p-dichlorodiphenyldichloroethylene [dichloro-
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diphenyldichloroethylene (p,p-DDE); purchased from Chem
Service], HCB (purchased from Pestanal Riedel-de Haën), -hexa-
chlorocyclohexane (sum of -HCH, -HCH, and -HCH, purchased
fromSigma-Aldrich), and lindane (purchased fromPestanalRiedel-de
Haën). The recovery percentages of samples spiked with a mixture of
XEs were higher than 80%. Agreement in the retention time in the
sample and in the reference standard was also required to confirm a
positive result. Results were expressed as nanograms per milliliter of
plasma and represent a mean of three individual injections of the same
sample. XE concentrations were expressed in wet-weight levels be-
cause lipid-standardized model produces large biases and appears
poorly suited for investigations in regard to cardiometabolic risk (17).
In AT samples [scAT and vAT collected during bariatric sur-
gery], XEs analysis was performed according to the method de-
scribed by Fernandes et al (18).
Cytokine ELISA
IL-6, IL-10, and monocyte chemotatic protein-1 (MCP1)
concentrations in plasma were measured using, respectively,
LEGEND MAX human IL-6, IL-10, and MCP1 ELISA kits (Bio-
Legend Inc), according to the manufacturer’s instructions.
Statistical analyses
Statistical analyses were performed using SPSS (22.0 version
statistical software; IBM Corp). Data were described as frequen-
cies and median (minimum, maximum). A Mann-Whitney test
was used to compare clinical and biological characteristics and
median of XEs between pre- and postmenopausal women. Fried-
man tests were used to compare XE levels in plasma, vAT, and
scAT, both in pre- and postmenopausal women. The strength of
the association between XE concentrations in plasma and AT
and various parameters was estimated by Spearman correlation
coefficients (RS). To evaluate contribution of the different vari-
ables to plasma concentration of MCP1 (log transformed) or
10-year CVD risk (log transformed), we performed a linear re-
gression analysis. The independent variables were included in the
models as a priori knowledge, ie, all the possible covariates with
a significant correlation with a dependent variable. A multivari-
able linear model were adjusted with age, vAT adipocyte area,
and sum of plasma XEs (XEs) as independent variables and
MCP1 (log transformed) as the dependent variable. Other linear
models were adjusted with the number of years of obesity evo-
lution, plasma MCP1 levels, and XEs in plasma as the inde-
pendent variable and 10-year CVD risk (log transformed) as the
dependent variable. All tests were two tailed and P  .05 was
regarded as significant.
Results
Clinical and biological parameters
The comparison of biological and clinical characteris-
tics between pre- and postmenopausal women is shown in
Table 1. Postmenopausal women were obese for more
years (37.0 vs 53.0 years, P  .001) than premenopausal
women. Regarding anthropometric parameters, there was
no difference in BMI and waist to hip ratio between the
two groups. vAT (4242.7 vs 3834.9 m2, P  .037) and
scAT (6625.4 vs 6134.9 m2, P  .036) adipocyte area
was higher in postmenopausal women. With respect to
glucose metabolism, postmenopausal women presented
higher fasting glucose (97.0 vs 91.0 mg/dL, P  .001) and
glycated hemoglobin (HbA1c) (5.8% vs 5.6%, P  .001)
than premenopausal women. There was no significant dif-
ference in HOMA-IR, but HOMA-2B was lower in post-
menopausal women (116.5% vs 156.6%, P  .003). We
found no significant difference in plasma lipid profile or in
either systolic or diastolic blood pressure between the two
groups. Regarding inflammatory markers, there were no
differences in IL-6, IL-10, MCP1, and hsCRP. As ex-
pected, the 10-year CVD risk was significantly higher in
postmenopausal women (13.3% vs 3.7%, P  .001)
(Table 1).
XEs in plasma
Among the selected XEs, in premenopausal women, the
most frequently detected compound in plasma was HCH
(sum of -HCH, -HCH, and -HCH), present in 79.5%
of the samples, followed by HCB, found in 72.6% of the
samples. On the contrary, aldrin could be measured only
in 6.8% of the samples. In postmenopausal women, the
most frequently detected compound found in plasma was
HCB, present in 87.5% of the samples, followed by
HCH, found in 52.1% of the samples. HCH lindane and
p,p-DDE were measured in 18.8% of the samples ob-
tained from postmenopausal women (Table 2). p,p-DDE
was not found in the plasma of the premenopausal women
and aldrin in postmenopausal women. However, when
the Mann-Whitney test was used to compare pre- and
postmenopausalwomen, themedianofHCHlindane level
(23.61 vs 5.81 ng/mL, P  .041) was significantly higher
in premenopausal women (Table 2). Median concentra-
tions of the sum of all XE (XEs) present in plasma did not
differ significantly between the pre- and postmenopausal
women (41.43 vs 35.71 ng/mL, P  .306), and for both
groups of women, HCB accounted for more than half of
the XE plasma burden.
XEs in vAT and scAT
We examined the presence of the five studied XEs both
in vAT and scAT samples in pre- and postmenopausal
women (Table 2). In premenopausal women, the percent-
age of samples with detectable concentrations of XEs was
90.4% with median values of 106.72 (0.28, 687.18) ng/g
of fat in vAT and 94.5% with median values of 61.62
(1.44, 368.06) ng/g of fat in scAT. In postmenopausal
women, the percentage of samples with detectable con-
centrations of XEs was 97.9% with median values of
141.62 (2.51, 601.32) ng/g of fat in vAT and 97.6% with
median values of 161.52 (0.41, 557.17) ng/g of fat in
scAT. The most frequently detected XEs, the HCH ap-







/article/100/5/1792/2829636 by guest on 18 April 2021
peared in 90.4% of vAT and scAT in premenopausal
women, also being detected in 95.8% of both vAT and
scAT samples in postmenopausal women. Regarding the
percentage of XE detection in vAT, HCH lindane was
found in 28.8% vs 22.9%, HCB in 5.5% vs 8.3%, aldrin
in 15.1% vs 29.2%, and p,p-DDE in 23.3% vs 33.3% of
vAT samples from pre- and postmenopausal women, re-
spectively. On the other hand, when comparing the abso-
lute concentration in each AT depot, we verified that the
medians of the XEs in vAT were not different between the
two groups. Concerning scAT, HCH lindane was found in
23.3% vs 17.0%, HCB was found in 5.5% vs 8.3%, aldrin
in 15.1% vs 29.2%, and p,p-DDE in 32.9% vs 43.8% of
the samples for pre- and postmenopausal women, respec-
tively. Concentrations of HCH (42.24 vs 98.51 ng/g of
fat, P  .018), p,p-DDE (1.55 vs 6.21 ng/g of fat, P 
.003), and XEs (61.62 vs 161.52 ng/g of fat, P  .020)
were higher in the scAT of postmenopausal women. In this
AT depot, HCH was the compound that contributed
most in most samples to the total scAT burden of XEs.
Finally, in premenopausal women the concentration of
XEs in vAT was significantly higher compared with scAT
(106.72 vs 61.62 ng/g of fat, P  .002). The plasma con-
centration of XEs was lower than that found in vAT and
scAT in pre- and postmenopausal women.
Association between XEs in plasma and AT
Paired-sample comparisons was made among the three
evaluated compartments (XEs levels in plasma and the
two ATs) both in premenopausal and postmenopausal
women (see Supplemental Table 1). In both pre- and post-
menopausal women, there was a different distribution of
XEs among the three analyzed locations. Although pre-
menopausal women had higher XE accumulation in vAT
followed by scAT and plasma, the levels of XEs in vAT and
scAT from postmenopausal women were similar, with
much lower plasma levels. The levels of XEs in both AT
depots were positively correlated in pre- (RS  0.488, P 
.01) and postmenopausal women (RS  0.545, P  .01).
In premenopausal women, XEs levels in vAT were posi-
tively correlated with plasma levels (RS  0.642, P  .01),
but plasma levels were not correlated with scAT XEs. In
Table 1. Clinical and Biological Characteristics of the Patients
Premenopausal Women Postmenopausal Women
P
ValueParameters n Median (Minimum, Maximum) n Median (Minimum, Maximum)
Age, y 73 37.0 (19.0, 59.0) 48 53.0 (36, 62) .001a
Obesity evolution, y 73 16.0 (5.0, 33.0) 48 24.0 (4.0, 49.0) .005a
Anthropometric and morphometric measurements
BMI, kg/m2 73 44.1 (36.8, 56.2) 48 44.6 (36.0, 60.0) .560
Waist to hip ratio 60 0.85 (0.75, 1.14) 37 0.90 (0.77, 1.08) .552
vAT adipocyte area, m2 70 3834.9 (2001.9, 7220.4) 47 4242.7 (2512.2, 6486.9) .037a
scAT adipocyte area, m2 73 6134.9 (2693.3, 10 294.2) 46 6625.4 (3511.6, 11 000.1) .036a
Plasma lipid profile
Total cholesterol, mg/dL 73 199.0 (114.0, 300.0) 48 210.5 (118.0, 357.0) .117
Total triglycerides, mg/dL 73 120.0 (53.0, 261.0) 48 114.0 (57.0, 274.0) .609
HDL cholesterol, mg/dL 73 51.0 (31.0, 81.0) 48 54.0 (32.0, 97.0) .061
LDL cholesterol, mg/dL 73 131.0 (58.0, 206.0) 48 136.0 (62.0, 290.0) .324
Glucose homeostasis
Fasting glycemia, mg/dL 73 91.0 (73.0, 153.0) 48 97.0 (75.0, 297.0) .001a
HbA1c, % 71 5.6 (4.8, 6.9) 45 5.8 (5.2, 10.3) .001a
HOMA-IR 70 2.2 (0.1, 7.8) 36 1.8 (0.4, 8.4) .354
HOMA-2B, % 70 156.6 (13.3, 370.7) 36 116.5 (42.5, 265.9) .003a
Blood pressure
Systolic blood pressure, mm Hg 58 130.0 (100.0, 171.0) 37 140.0 (109.0, 184.0) .098
Diastolic blood pressure, mm Hg 58 80.0 (60.0, 120.0) 37 80.0 (63.0, 155.0) .230
Inflammatory parameters
IL-6, pg/mL 53 32.7 (4.3, 129.5) 45 30.9 (7.5, 99.0) .695
IL-10, pg/mL 64 4.8 (0.3, 104.0) 45 3.4 (0.1, 117.4) .267
IL-6 to IL-10 ratio 52 5.17 (0.47, 317.96) 42 7.60 (0.44, 213.13) .076
MCP1, pg/mL 67 113.8 (17.0, 792.7) 48 106.1 (20.0, 417.7) .628
Other parameters
hsCRP, mg/L 45 3.4 (0.3, 37.0) 29 4.2 (0.3, 45.0) .373
Estradiol, pg/mL 22 59.4 (15.0, 193.0) 32 26.5 (10.0, 110.0) .030a
Monocytes, % 66 6.0 (0.4, 9.8) 44 6.1 (0.2, 10.2) .707
10-Year CVD risk, % 51 3.7 (0.3, 27.8) 37 13.3 (1.9, 34.7) .001a
Ten-year CVD risk was calculated according to D’Agostino et al (15).
a Statistical analysis was performed with a Mann-Whitney test: P  .05.
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contrast, in postmenopausal women plasma XEs levels
were positively correlated with XEs levels present in either
AT compartment (Table 3). The strongest association ob-
served both in pre- and postmenopausal women was that
between vAT and plasma XE levels.
XE levels were associated with metabolic
dysfunction
The associations between XE levels and the patients’
clinical and biochemical parameters were also evaluated.
We show correlations between the two most frequently
detected XEs in each compartment and biological param-
eters (see Supplemental Tables 2–4). In premenopausal
women, the vAT XEs concentration was significantly
and positively correlated with HbA1c and the count of
plasma monocytes and inversely correlated with plasma
IL-10. However, no significant correlation was found be-
tween scAT XEs and the different parameters. Plasma
XEs were positively correlated with age, vAT adipocyte
area, plasma IL-10, MCP1, and 10-year CVD risk and
negatively correlated with HOMA-2B. In postmeno-
pausal women, the only significant correlations found
were a positive association between vAT XEs and age
and a negative association between plasma XEs and the
IL-6 to IL-10 ratio (Table 4).
Plasma XE levels were associated with
inflammation and 10-year CVD risk in
premenopausal women
In premenopausal women, the concentration of MCP1
was positively correlated with plasma XEs (Table 4). In
the linear regression model analysis, only XEs plasma
levels (  0.006, P  .018) remained statistically asso-
ciated with plasma MCP1, even when adjusted for age and
vAT adipocyte area (Table 5), highlighting the fact that
XEs are independent risk factors for inflammation. On the
other hand, the 10-year CVD risk correlated positively
with XEs plasma levels in premenopausal women (Table
Table 2. XE Levels in Plasma (Nanograms per Milliliter) and in Both vAT and scAT (Nanograms per Grams of Fat) of
the 121 Patients
%a Premenopausal Women %a Postmenopausal Women P Value
Plasma
HCH 79.5 16.20 (2.98, 57.83) 52.1 14.18 (4.41, 26.38) .336
HCH lindane 16.4 23.61 (2.17, 55.53) 18.8 5.81 (0.46, 33.06) .041b
HCB 72.6 31.52 (21.56, 95.80) 87.5 29.19 (20.75, 58.76) .195
Aldrin 6.8 0.12 (0.04, 0.38) LD
p,p-DDE LD 18.8 7.10 (4.61, 26.64)
XEs 93.2 41.43 (2.17, 209.16) 97.9 35.71 (2.80, 101.64) .306
vAT
HCH 90.4 103.69 (0.01, 485.67) 95.8 99.57 (1.94, 399.48) .947
HCH lindane 28.8 15.19 (0.59, 87.44) 22.9 33.96 (5.19, 338.39) .051
HCB 5.5 87.10 (84.91, 104.00) 8.3 60.67 (0.33, 149.23) .343
Aldrin 15.1 11.41 (0.47, 48.87) 29.2 6.79 (0.57, 55.72) .267
p,p-DDE 23.3 24.83 (1.26, 257.52) 33.3 15.20 (2.02, 289.51) .873
XEs 90.4 106.72 (0.28, 687.18) 97.9 141.62 (2.51, 601.32) .442
scAT
HCH 90.4 42.24 (1.29, 330.30) 95.8 98.51 (0.34, 458.94) .018b
HCH lindane 23.3 30.89 (6.47, 262.81) 17.0 44.77 (24.92, 271.86) .157
HCB 5.5 104.46 (92.79, 121.77) 8.3 77.85 (14.72, 160.30) .343
Aldrin 12.3 23.53 (2.17, 112.90) 22.9 9.00 (1.76, 88.85) .175
p,p-DDE 32.9 1.55 (0.19, 30.14) 43.8 6.21 (0.30, 308.03) .003b
XEs 94.5 61.62 (1.44, 368.06) 97.6 161.52 (0.41, 557.17) .020b
All data are medians (minimum, maximum).
a Percentage of the total number of positive samples.
b Values are presented as median (minimum, maximum) (P  .05, statistical analysis with Mann-Whitney test).
Table 3. Correlation and Comparison Between Levels of XEs Present Simultaneously in Both vAT (Nanograms per
Gram of Fat) and scAT (Nanograms per Gram of Fat) and Plasma (Nanograms per Milliliter)
%a Premenopausal Women %a Postmenopausal Women
XEs, vAT vs scAT 86.3 0.488b 95.8 0.545b
XEs , vAT vs plasma 83.6 0.642b 95.8 0.625b
XEs , scAT vs plasma 87.7 0.084 95.8 0.416b
a Percentage of the total number of positive samples in both vAT and scAT.
b Statistical analysis with Spearman’s correlation (P  .01).
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4). In the multivariate linear model, XEs plasma levels
were also significantly associated with 10-year CVD risk
(  0.012, P  .009), even when adjusted for the time of
obesity and MCP1. A significant interaction (  0.001,
P  0.006) between MCP1 and the time of obesity seems
to occur, even after adjustment for XEs plasma levels
(Table 6) in premenopausal women. Considering post-
menopausal women in multivariate models, no indepen-
dent variables were significantly associated with MCP1 or
with 10-year CVD risk (Table 4). Considering the 44 pre-
menopausal woman included in the linear regression
Table 6. Coefficients From Linear Regression Model





 P Value  P Value
XEs in plasma,
ng/mL
0.012 .009 0.005 .384
Obesity evolution, y 0.014 .016 0.000 .982
MCP1, pg/mL 0.135 <.001 0.017 .517
Obesity evolution,
y, MCP1, pg/mLa
0.001 .006 0.000 .615
-Values from linear regression model is reported. Significant P values
are shown in bold.
a Adjusted for all variables present in table.
Table 4. Correlation of Clinical and Biological Characteristics With XE Levels in vAT and scAT (Nanograms per
Gram of Fat) and Plasma (Nanograms per Milliliter) of Premenopausal and Postmenopausal Women
Parameters
Premenopausal Women Postmenopausal Women
vAT XEs scAT XEs Plasma XEs vAT XEs scAT XEs Plasma XEs
Age, y 0.077 0.102 0.368a 0.351b 0.074 0.052
Obesity evolution, y 0.131 0.097 0.172 0.012 0.046 0.219
Anthropometric and morphometric measurements
BMI, kg/m2 0.115 0.027 0.001 0.055 0.106 0.016
Waist to hip ratio 0.105 0.043 0.076 0.026 0.070 0.158
vAT adipocyte area, m2 0.014 0.109 0.278b 0.264 0.208 0.059
scAT adipocyte area, m2 0.000 0.201 0.109 0.047 0.045 0.138
Plasma lipid profile
Total cholesterol, mg/dL 0.035 0.091 0.052 0.024 0.017 0.115
Total triglycerides, mg/dL 0.041 0.004 0.019 0.107 0.206 0.221
HDL cholesterol, mg/dL 0.035 0.111 0.174 0.051 0.082 0.039
LDL cholesterol, mg/dL 0.101 0.148 0.083 0.060 0.023 0.156
Glucose homeostasis
Fasting glycemia, mg/dL 0.066 0.048 0.074 0.134 0.186 0.129
HbA1c, % 0.252b 0.232 0.085 0.116 0.154 0.037
HOMA-IR 0.057 0.121 0.234 0.01 0.243 0.164
HOMA-2B, % 0.050 0.096 0.250b 0.173 0.097 0.162
Blood pressure
Systolic blood pressure, mm Hg 0.136 0.175 0.165 0.071 0.127 0.031
Diastolic blood pressure, mm Hg 0.103 0.118 0.255 0.159 0.166 0.116
Inflammatory parameters
IL-6, pg/mL 0.058 0.152 0.172 0.138 0.015 0.030
IL-10, pg/mL 0.279b 0.017 0.328b 0.108 0.131 0.291
IL-6 to IL-10 ratio 0.259 0.062 0.131 0.138 0.158 0.365b
MCP1, pg/mL 0.170 0.004 0.285b 0.053 0.039 0.008
Other parameters
hsCRP, mg/L 0.228 0.158 0.231 0.047 0.019 0.005
Estradiol, pg/mL 0.122 0.022 0.339 0.179 0.311 0.232
Monocytes, % 0.360a 0.096 0.054 0.220 0.058 0.014
10-Year CVD risk, % 0.211 0.098 0.363b 0.185 0.155 0.142
Ten-year CVD risk was calculated according to D’Agostino et al (12).
a P  .01 (statistical analysis with Spearman’s correlation).
b P  .05 (statistical analysis with Spearman’s correlation).
Table 5. Coefficients From Linear Regression Model





 P Value  P Value
XEs in plasma, ng/mL 0.006 .012 0.000 .966
Age 0.017 .108 0.012 .451
vAT adipocyte 0.000 .845 0.000 .870
-values from a linear regression model are reported. Significant P
values are shown in bold.
a Adjusted for all variables present in table.
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model with Ln 10-year CVD risk as dependent variable,
we studied the power of testing the predictor XEs in
plasma (nanograms per milliliter), in the presence of two
other predictors (obesity evolution, MCP1). The power of
the test of a regression coefficient depends on the error SD,
the SD of the predictor itself, and the multiple correlation
between that predictor and other predictors in the model
(related to the variance inflation factor). These parameters
were estimated based on the sample enrolled. For an  of
.05 and a power of 0.80, a sample size of n  44 will detect
a regression coefficient of 0.013. Considering the 36 post-
menopausal woman included in the linear regression
model with Ln 10-year CVD risk as a dependent variable,
we studied the power of testing the predictor XEs in
plasma (nanograms per milliliter), in the presence of two
other predictors (obesity evolution and MCP1). With the
parameters estimated with the sample enrolled, for an  of
.05 and a power of 0.80, a sample size of n  36 will detect
a regression coefficient of 0.015.
Discussion
In the present study, we carried out a novel and compre-
hensive assessment in pre- and postmenopausal women of
the distribution and putative effects of several XEs that are
known to be preferentially accumulated in the AT. We
showthat several environmental estrogens suchas HCH,
HCH lindane, HCB, aldrin, and p,p-DDE can be cur-
rently detected in biological samples obtained from obese
patients, although their use has long been banned. Anal-
ysis of the association of health-related outcomes with
XEs in the different biological samples was considered
superior to the analysis of individual compounds because
essentially all humans are exposed to many different XEs
at the same time (3, 4), although perhaps in different rel-
ative concentrations.
A previous work from our group (11) demonstrated
that persistent organic pollutants, some of which have
xenoestrogenic activity, accumulated preferentially in
vAT when women were considered regardless of meno-
pausal status. In the present study, we were able to dem-
onstrate that the distribution of XEs changes with meno-
pausal status. For the compounds analyzed here, we can
observe that this is true for premenopausal women but not
postmenopausal women whose XE levels in scAT are sim-
ilar to those in vAT and significantly higher than those
found in the scAT of premenopausal women. On the other
hand, this observation has important practical implica-
tions because it suggests that scAT, despite being an easily
accessible compartment for determination of contamina-
tion levels, is not representative of the XE distribution in
deeper AT depots, in accordance with different studies
(19, 20). Plasma levels of XEs also did not reflect total
levels accumulated in other compartments, highlighting
that using plasma XE levels to estimate exposure may be
misleading as well. Apart from being lower than AT levels,
the type of compound present in plasma does not mimic
the pattern accumulated in AT, possibly due to differences
in solubility and toxicokinetics, resulting in different po-
tential toxicities.
In premenopausal women there is a significant positive
correlation between XEs in vAT and plasma but not with
XEs in scAT. This association makes sense in that vAT
adipocytes are metabolically more active and more sensi-
tive to lipolysis than scAT adipocytes (21). On the other
hand, plasma XEs correlated both with vAT and scAT XEs
in postmenopausal women, suggesting that the increased
turnover of the AT after menopause, including higher li-
polysis rate due to decreased estrogens (22), may contrib-
ute to the concentration of XEs in scAT. Indeed, this pat-
tern change may be a consequence of a changing hormonal
milieu because of the menopausal transition, but it may
also be modulated by the presence of XEs. Nevertheless, it
seems to accompany a dysfunctional AT in this subgroup
of women.
We observed that although older, postmenopausal
women present higher metabolic dysfunction, as confirmed
by our results, we found that XEs are positively associated
with markers of impaired metabolism and with CVD risk in
younger, premenopausal women. This suggests that the ef-
fect of these compounds may be independent of the decline
of metabolic function that occurs with age.
Fat accumulated in vAT, in comparison with scAT, is
known to positively correlate with metabolic complica-
tions, such as CVD, hypertension, and type 2 diabetes
(23). Indeed, because XEs in vAT of premenopausal
women were found to be more tightly associated with
markers of worst metabolic profile compared with XEs in
scAT, namely glucose homeostasis and inflammatory pa-
rameters, this might suggest that the presence of these
compounds in vAT contributes to local toxicity and dys-
function and potentially favors the metabolic complica-
tions associated with obesity (6). Therefore, our study
highlights the contribution of chronic internal exposure of
obese subjects to XEs as possible additional factors lead-
ing to AT dysfunction.
In metabolically unhealthy obesity, adipocyte expan-
sion occurs through hypertrophy with overproduction
and secretion of signals that recruit immune cells, namely
macrophages, leading to increased circulatory proinflam-
matory (eg, IL-6 and MCP1) and decreased antiinflam-
matory (IL-10) factors that contribute to local AT inflam-
mation and to systemic low-grade inflammation (24, 25).
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Indeed, plasma XEs were correlated with increased vAT
adipocyte area, a known marker of adipocyte dysfunction
(26, 27).
Additionally, it has been proposed that XEs in AT can
be involved in inflammatory activation/perpetuation, a
critical condition for metabolically unhealthy AT (28). In
accordance, we have found that in premenopausal women
the presence of XEs in vAT and plasma may contribute to
a more proinflammatory status. Plasma XEs correlated
positively with MCP1 levels, which is compatible with
higher production by activated cells in the AT. In fact, the
mesenteric AT is a major producer of MCP1, which can
modulate macrophage trafficking and activation during
obesity-related inflammation (29). Furthermore, proin-
flammatory chemokines such as MCP1 are highly ex-
pressed by hypertrophic adipocytes accelerating migra-
tion and homing of bone marrow-derived monocytes/
macrophages to the AT (30). It is worth highlighting that
in the linear regression model, adjustment for age and vAT
adipocyte area did not modify the association between
plasma XEs and MCP1 levels.
Once again, the increase in vAT XEs is correlated with
the increase in the number of monocytes in circulation, a
possible intermediate step to their migration to the AT.
This reinforces the hypothesis that XE exposure, through
its effect on the immune system, may contribute to the high
rate of metabolic disorders (31). The negative association
between vAT XEs and plasma IL-10 levels adds to this
evidence, although an opposite association was observed
with plasma XEs.
In addition to inflammatory activation, dysfunctional
AT also displays insulin resistance (32). In the same line,
we have observed a positive association between vAT XEs
and HbA1c. We also observed a negative relationship be-
tween plasma XEs and HOMA-2B. Accordingly, several
researches provide evidence on possible actions of XEs on
-cell function and insulin resistance (33, 34). An obser-
vational study of Greenland Inuits highly exposed to en-
vironmental pollutants showed associations of some XEs
with HOMA-2B, but not with HOMA-IR (35), indicating
that the primary mechanism by which XEs increase the
risk of type 2 diabetes is by modulating -cell function.
Furthermore, the association of plasma, but not vAT, XEs
with this marker highlights the fact that different com-
pounds are present in plasma and AT and that plasma XEs
have many possible targets for toxicity.
Another interesting fact is that XE concentration is not
BMI dependent. This is an important result because it
demonstrates that body weight per se is not the primary
factor explaining plasma XE concentration (36). Plasma
XE levels may potentially be affected by a number of fac-
tors including the degree and source of exposure, the time
since exposure occurred, genetic differences among indi-
viduals in rates of metabolism (37), and the number of
pregnancies and breast-feeding practices (38).
Our results support the hypothesis that XEs increase
systemic inflammation/AT dysfunction in premenopausal
women, which may aggravate metabolic status and induce
target organ damage. Indeed, plasma XEs helped predict
CVD risk, even after adjustment for plasma MCP1 and the
time of obesity. In addition, these results indicate that XE
exposure or release from AT and inflammation may be
independent factors for CVD risk, suggesting that in-
creased plasma XEs may at least partially account for the
inflammation and risk elicited by obesity in premeno-
pausal women with the same time of obesity.
As mentioned earlier, the compounds evaluated in this
study have been highlighted as endocrine disruptors in-
terfering with estrogens, although also possessing other
biological activities (39). However, their capacity to in-
terfere with estrogens’ actions is complex, given that these
compounds may behave differently, often with opposing
actions, if in the presence of absence of the natural hor-
mone and/or depending on its concentration (40). This
possibly underlines the fact that most of the associations
of XEs with markers of metabolic deterioration observed
herein were in the premenopausal women subgroup, lead-
ing to the speculation that the effect of XEs is more rele-
vant when in the presence of preserved estrogen endocrine
signaling.
Our findings also suggest that XEs and not obesity
alone may contribute to increase CVD risk and inflam-
mation, especially in premenopausal women, and thus,
these chemicals may have a potential role in the later de-
velopment of cardiometabolic disease in obese women.
Moreover, the associations observed are compatible with
the endocrine disruptor character of these compounds by
compromising the dynamic protective physiological func-
tion of estrogens, leading to the release and redistribution
of these pollutants. We also provide new insights into the
profile and kinetics of XEs and their putative pathogenic
effects according to menopausal status. This is in line with
the observation that the relationship between 10-year
CVD risk and plasma concentrations of MCP1 tended to
be weakened with the time of obesity evolution in pre-
menopausal women.
We acknowledge that the present study is not without
limitations: 1) the patients were at the end of the line of
obesity treatment, which limits the generalization of our
findings to the overall population, and 2) there were mul-
tiple comparisons made in this study; however, because
the present study is an exploratory study, we believe that
it is not needed to include the correction for multiple com-
parisons, and thus, the significant results found in this
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study should be verified in further confirmatory studies
(34). Nonetheless, our study has significant assets regard-
ing the large sample size, the characterization of environ-
mental exposures in three tissue compartments (plasma,
vAT, and scAT) in obese women undergoing bariatric sur-
gery, and the analysis of the results according to meno-
pausal status, exploring a differential link to the metabolic
abnormalities and cardiovascular risk.
Importantly, there is a need to extend the knowledge of
the mechanisms of action of XEs, which may alter meta-
bolic function, which will open novel directions for the
prevention, and treatment of metabolic disease. The ques-
tion of whether XEs could serve as biomarkers represent-
ing a novel tool to predict cardiometabolic risk remains to
be fully answered, but if these findings are reproducible in
different populations, it means that as early as possible,
any effort to reduce exposure to XEs would be necessary
to decrease the social burden of cardiometabolic disease.
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